Implementation of NICE Technology Appraisal 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia.

I refer to the above NICE guidance and the required arrangements for its implementation.

Background

NICE TA 545 sets out arrangements for the use of gemtuzumab ozogamicin for untreated acute myeloid leukaemia. In line with Circular HSC (SQSD) 2/13, the HSCB is required to issue a Service Notification for this NICE TA to all relevant providers and stakeholders. The attached Service Notification now represents the Department’s formal policy position (see annex 1).

Resource Implications

Any additional resources associated with the introduction of the technology will be incorporated in the Trust financial allocation for 2018/19 and beyond.

Action required by Health and Social Care

Trusts should now take forward the implementation of NICE TA 545 in accordance with the enclosed service notification with immediate effect. The Board’s expectation is that proportionate implementation arrangements will be established on receipt of this correspondence.
In particular, within three months ensure that: targeted dissemination takes place; a clinical/management change leader has been agreed; and a proportionate implementation plan is in place.

**Assurance arrangements**

The Board will seek direct assurances from Trusts on an ongoing basis regarding the actions outlined above.

Thank you for your attention with this matter. If you have any queries please contact Jonathan Houston (Tel: 95 36 3191) in the HSCB Commissioning Directorate in the first instance.

Yours sincerely

Dr Miriam McCarthy
Director of Commissioning

Cc  Chief Medical Officer
    Chief Executive Patient and Client Council
    Chief Executive/Postgraduate Dean, NIMDTA
    Chief Executive, NICPLD
    Chief Executive, NIPEC
    Chief Executive, NIBTS
    Chief Executive, RQIA
    Chief Executive, PHA
    Senior Management Team, HSCB
    Assistant Directors of Commissioning, HSCB

Encs